Hybrid SPECT/CT imaging of sentinel nodes in esophageal cancer: first results.

Hybrid SPECT/CT imaging of sentinel nodes in esophageal cancer: first results. Acta Radiol. 2013 Mar 18; Authors: Tsai JA, Celebioglu F, Lindblad M, Lörinc E, Nilsson M, Olsson A, Lundell L, Axelsson R Abstract BackgroundSentinel node (SN) biopsy in esophageal cancer has the potential of becoming an important tool for ruling out the presence of lymph node metastases in patients opted for less extensive surgery without neoadjuvant treatment.PurposeTo investigate preoperative SN imaging in esophageal cancer using hybrid single photon emission computed tomography (SPECT)/CT.Material and MethodsEight patients with esophageal cancer scheduled for thoracoabdominal esophagectomy after neoadjuvant treatment, underwent endoscopic submucosal injection of (99m)Tc-nanocoll the day before surgery, followed by imaging with SPECT/CT for preoperative detection. Intraoperative detection of SNs was performed with a gamma probe.ResultsSNs were identified by SPECT/CT in 7/8 cases (88%) and by gamma probe in all cases. The median number of identified lymph node stations with SN in the operating field was 1 (range 0-2) for SPECT/CT and 1 (range 1-3) for gamma probe. The median distance between the perceived location of the respective SN according to SPECT/CT and the location identified with the gamma probe was
Source: Acta Radiologica - Category: Radiology Authors: Tags: Acta Radiol Source Type: research

Related Links:

Abstract Chemoradiotherapy (CRT) is a valuable treatment option for localized esophageal cancer. Conventional baseline chemotherapy for this type of cancer includes cisplatin and fluorouracil. Recently, CRT with leucovorin-fluorouracil-oxaliplatin (FOLFOX) has become popular due to its convenience and lower toxicity. In Japan, the use of oxaliplatin for esophageal cancer is not yet approved, so experience with this treatment is limited to cases with colorectal cancer. As such patients are not usually included in clinical trials, little is known on the efficacy and safety of this treatment for this patient subpopul...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Condition:   Esophageal Cancer Intervention:   Device: Cytosponge cell collection device Sponsor:   Centre of Postgraduate Medical Education Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion.Detection of CDK12‐LOF genomic alterations and their association with FTDs in a diverse spectrum of malignancies suggests that immunotherapy approaches targeting FINAs derived from CDK12‐associated FTDs may be a broadly applicable strategy that could be explored across cancer types in a tumor‐agnostic manner.Implications for Practice.CDK12 inactivation in ovarian and prostate cancer results in the generation of focal tandem duplications, which can cause fusion‐induced neoantigens. In prostate cancer, CDK12 alterations have demonstrated promise as a potential predictive biomarker for response to immune ch...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Cancer Diagnostics and Molecular Pathology Source Type: research
Gastric and oesophageal cancer represent a significant burden of global disease: they are the 3rd and 6th ranking causes of worldwide cancer mortality respectively, accounting for over 1.2 million deaths in 2018[1]. Whilst traditionally these diseases have been managed as distinct entities, many of the clinical challenges are shared. They are both associated with non-specific symptoms, presenting at an advanced stage where curative treatment is challenging or impossible. The key diagnostic test, endoscopy, is impractical for unselected screening purposes and there are considerable efforts to improve early diagnosis by other means[2].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Laboratory-Clinic Interface Source Type: research
AbstractPurpose of ReviewThis paper seeks to highlight GI motility disorders that are frequently present in patients with a malignancy. GI dysmotility can occur due to the cancer itself or as a consequence of medical and surgical treatments. Often, symptoms are nonspecific and the diagnosis requires a high index of suspicion. The goal of the paper is to review the common motility problems seen in patients with cancer, their clinical manifestations, and options for management.Recent FindingsStudies show that newer endoscopy techniques such as endoscopic mucosal dissection can cause esophageal dysmotility. Opioid-induced con...
Source: Current Gastroenterology Reports - Category: Gastroenterology Source Type: research
Conclusion DEVLB is a distinct phenotype seen in a small but significant proportion of individuals with dysplastic Barrett’s esophagus. Patients with DEVLB have widespread LGD, with many having areas of focal HGD or early cancer within this area. We believe these patients are best treated with extensive EMR of the visibly abnormal area. [...] © Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Endoscopy International Open - Category: Gastroenterology Authors: Tags: Original article Source Type: research
ConclusionsCharacterization of psoas muscles as a surrogate marker for sarcopenia on baseline18F-FDG PET/CT imaging is relatively easily obtained and may offer additional prognostic value in patients with EAC.
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
We present a contemporary analysis of risk of fatal stroke among more than 7.5 million cancer patients and report that stroke risk varies as a function of disease site, age, gender, marital status, and time after diagnosis. The risk of stroke among cancer patients is two times that of the general population and rises with longer follow-up time. The relative risk of fatal stroke, versus the general population, is highest in those with cancers of the brain and gastrointestinal tract. The plurality of strokes occurs in patients older than 40 years of age with cancers of the prostate, breast, and colorectum. Patients of any ag...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
BOSTON (CBS) — According to a new study published in the journal Cancer, even light to moderate alcohol intake has been linked to a higher risk of cancer. Researchers at the University of Tokyo and the Harvard T.H. Chan School of Public Health looked at data on over 60,000 cancer patients in Japan. They found drinking as little as one drink a day for 10 years or two drinks a year for five years, was associated would increase overall cancer risk by five percent, such as cancers of the colon, stomach, breast, prostate, and esophagus. Cancer risk was lowest with no alcohol consumption.
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Healthwatch Seen On WBZ-TV Syndicated Local Cancer Dr. Mallika Marshall Drinking Source Type: news
Conditions:   Esophageal Cancer;   Nutritional Deficiency Intervention:   Dietary Supplement: prosure Sponsor:   THEODOROU DIMITRIOS Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | CT Scan | Esophagectomy | Esophagus Cancer | Nanotechnology | Neoadjuvant Therapy | Radiology | SPECT